0

Paratek (PRTK) Antibacterial Drug Meets All Endpoints In Late-Stage Study

On Monday, Paratek Pharmaceuticals (NASDAQ:PRTK) announced positive phase 3 results in patients with acute bacterial skin and skin structure infections — ABSSSI. The trial met on all primary and secondary endpoints of the study. In my opinion, that should push the FDA… Continue Reading

0

Conatus Pharmaceuticals (CNAT) Receives Orphan Drug Designation For Rare Liver Disease

On Monday, Conatus Pharmaceuticals (NASDAQ:CNAT) announced that it had received orphan drug designation for its rare liver disease drug. The drug in question is a pre-clinical candidate known as IDN-7314. This drug is being developed by Conatus to treat a… Continue Reading

0

Adamis Pharmaceuticals (ADMP) Skyrockets 53% On FDA Approval

On Thursday, Adamis Pharmaceuticals (NASDAQ:ADMP) skyrocketed to a one-year high of 53% after the company’s allergic reaction treatment gained FDA approval. Adamis announced approval for the pre-filled Epinephrine drug known as Symjepi. The reason why the approval was so significant… Continue Reading

0

NewLink Genetics Sinks 40% As Roche Axes Biotech Deal

On Thursday, NewLink Genetics (NASDAQ:NLNK) received notice from Roche (OTCMKTS:RHHBY) that it would be terminating the license agreement on work with the GDC-0919 compound. This sent shares of NewLink tumbling by more than 40%, because the deal was a large… Continue Reading

0

Inovio Pharmaceuticals Begins Phase 3 Trial With FDA Green Light

Recently, Inovio Pharmaceuticals (NASDAQ:INO) announced that it had received notice from the FDA that it could begin testing on its phase 3 clinical trial product. The product in question VGX-3100 is a vaccine made by Inovio to treat cervical dysplasia… Continue Reading

0

Dynavax Technologies (DVAX) Announces Positive Melanoma Results In Early Stage Study

Dynavax Technologies (NASDAQ:DVAX) announced positive phase 1b/2 results in patients with melanoma. The trial was testing a combination of Dynavax’s SD-101 drug in combination with Merck’s KEYTRUDA. The drug combination reported positive results in melanoma patients, which is why the… Continue Reading

0

Teva Pharmaceuticals (TEVA) Posts Positive Phase 3 Results In Migraine Study

Teva Pharmaceuticals (NYSE:TEVA) announced positive phase 3 results for its migraine study. The drug that was tested in the phase 3 trial in patients with migraine is known as fremanezumab. With the positive phase 3 results, the company is looking… Continue Reading

0

EnteroMedics (ETRM) Acquires Medical Device Maker BarioSurg

On Tuesday, EnteroMedics (NASDAQ:ETRM) announced that it had acquired California medical device maker BarioSurg Incorporated. The reason for the acquisition is because BarioSurg makes a medical device that helps to treat obesity. This falls in line with Enteromedics who also… Continue Reading